It's not a big deal for the first world, but poorer nations may hold out for future vaccines that remain stable at higher temperatures and only require a single dose.

Merck is working on a one-dose pill, but that's not expected before mid-2021.

There's micro encapsulation for vaccines.[1][2] The vulnerable active molecule can be put inside a coating that is stable in storage but dissolves after injection.

[1] https://www.academia.edu/33376119/Microencapsulation_of_Vacc...

[2] https://www.sciencedirect.com/topics/immunology-and-microbio...

Valid point, but I feel there's never been a better time for massively pushing this vaccine (after proper testing and regulatory approval, of course) to medium/low income countries.

Winter should make it much easier in managing the temperature range stability required for storing/shipping the vaccine, especially in countries around the equatorial region.

Doing it in late spring/summer will not be a good idea (assuming a better vaccine doesn't come out by then).

That's a big issue. The N95 mask shortage demonstrates that the US manufacturing industry has far less surge capacity for simple items than previously thought.